Bangor Savings Bank raised its position in shares of Pfizer Inc. (NYSE:PFE) by 16.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,076 shares of the biopharmaceutical company’s stock after buying an additional 6,333 shares during the period. Bangor Savings Bank’s holdings in Pfizer were worth $1,766,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Natixis acquired a new stake in shares of Pfizer during the second quarter worth about $258,466,000. Integrated Wealth Concepts LLC increased its position in shares of Pfizer by 14.2% during the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after purchasing an additional 8,445 shares in the last quarter. Halsey Associates Inc. CT increased its position in shares of Pfizer by 73.8% during the third quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock worth $1,592,000 after purchasing an additional 18,822 shares in the last quarter. Whitnell & Co. increased its position in shares of Pfizer by 390.0% during the third quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock worth $1,815,000 after purchasing an additional 40,200 shares in the last quarter. Finally, IHT Wealth Management LLC increased its position in shares of Pfizer by 20.5% during the third quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock worth $2,595,000 after purchasing an additional 12,291 shares in the last quarter. Institutional investors and hedge funds own 70.19% of the company’s stock.
PFE traded down $0.56 during trading on Wednesday, reaching $37.58. The company’s stock had a trading volume of 32,410,913 shares, compared to its average volume of 23,252,514. The company’s fifty day moving average price is $39.34 and its 200-day moving average price is $37.92. The company has a market capitalization of $220.37 billion, a price-to-earnings ratio of 13.14, a price-to-earnings-growth ratio of 4.16 and a beta of 0.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $44.56.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 28th. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.02). The firm had revenue of $12.69 billion for the quarter, compared to analysts’ expectations of $12.73 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. Pfizer’s revenue was down 9.2% compared to the same quarter last year. During the same period last year, the firm earned $0.64 EPS. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a dividend of $0.38 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. This represents a $1.52 annualized dividend and a dividend yield of 4.04%. Pfizer’s payout ratio is 48.00%.
PFE has been the topic of a number of research reports. Credit Suisse Group reissued a “hold” rating and set a $41.30 price target on shares of Pfizer in a report on Wednesday, November 6th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a report on Tuesday, October 1st. Bank of America initiated coverage on Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and set a $37.00 price target on shares of Pfizer in a report on Tuesday. Finally, Royal Bank of Canada began coverage on Pfizer in a report on Monday, January 6th. They set an “outperform” rating and a $46.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $42.72.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
